U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07566195) titled 'Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations' on April 29.
Brief Summary: ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
Eligible participants must have completed one of the predecessor studies.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease
COPD
Intervention:
DRUG: Tozorakimab Dose Regimen 1
Participants previously randomised in the MIRANDA predecessor study will...